This site is intended for UK-registered healthcare professionals only
Media partners:
GPnotebook

Prescribing Information and adverse events reporting information can be found at the bottom of this page.
This website has been developed and funded by A. Menarini Farmaceutica Internazionale SRL.
The media partners for this activity are GPnotebook and Diabetes on the net.

What Invokana can offer
Meet Gemma – T2D case study
Learn more about Invokana
Contact us
Access the IDSC page

Explore the power of HbA1c control with Invokana® (canagliflozin)

Empowering control where it counts

Control of HbA1c

Significant reduction of HbA1c vs metformin, sulfonylurea, DPP4 inhibitors and other SGLT2 inhibitors, in a network meta-analysis1,2

Achieve cardiovascular protection

Poor glycaemic control in T2D is a key risk factor for developing cardiovascular complications3–5†‡§

Protect against adverse renal outcomes

Persistent hyperglycaemia is a leading cause for chronic kidney disease and end stage renal disease in T2D3,4,6§

Meet Gemma

A 46-year-old mum of two who has been living with T2D for three years. Watch this short video to learn more about how you can help patients like Gemma to not only get their HbA1c under control, but to also reduce the risk of CV events and slow progression to kidney disease.

Learn more about Invokana

Contact your local representative to learn more about how Invokana can protect your patients living with T2D: [email protected]

Abbreviations

CV: cardiovascular; DPP-4: dipeptidyl peptidase 4; eGFR: estimated glomerular filtration rate; ESKD: end-stage kidney disease; HbA1c: glycated haemoglobin A1c; IDSC: Improving Diabetes Steering Committee; MACE: major adverse cardiovascular events; MI: myocardial infarction; T2D: type 2 diabetes.

References and footnotes

  1. Invokana. Summary of Product Characteristics.
  2. Zaccardi F, et al. Diabetes Obes Metab. 2016; 18:783–794.
  3. Neal B, et al. N Engl J Med. 2017;377: 644–657.
  4. Perkovic V, et al. N Engl J Med. 2019;380:2295–2306.
  5. Khanal KM, et al. PLoS ONE. 2022;17:e0271888.
  6. Kumar M, et al. Cureus. 2023;15:e45615.
  • MACE is a composite of nonfatal stroke, nonfatal MI, and CV death.3,4
  • CANVAS Program. Integrated data from two trials (CANVAS and CANVAS-R) involving a total of 10,142 participants with T2D and high CV risk. Participants in CANVAS were randomly assigned to receive canagliflozin 300 mg, 100 mg, or matching placebo; participants in CANVAS-R were randomised to canagliflozin, administered at an initial dose of 100 mg daily with an optional increase to 300 mg starting from week 13, or matching placebo. Mean follow-up was 188.2 weeks. Canagliflozin on a background of standard of care treatments for diabetes and atherosclerotic cardiovascular disease. CV (MACE: the composite of CV death, nonfatal MI, and nonfatal stroke) and renal endpoints (doubling of serum creatinine, need for renal-replacement therapy, and renal death).3
  • CREDENCE Study. Randomised, double-blind, placebo-controlled, multicentre clinical trial. Patients with T2D and albuminuric chronic kidney disease received canagliflozin, at a dose of 100 mg daily or placebo. Canagliflozin on a background of standard of care treatments for diabetic kidney disease, including angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Renal outcomes: time to first occurrence of ESKD (defined as an eGFR <15 mL/ min/1.73 m2, initiation of chronic dialysis or renal transplant), doubling of serum creatinine, and renal or CV death.4
  • Based on association studies. Causality between glycaemic control and cardiovascular/renal outcomes is not directly established in the cited references.

Invokana® (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In addition to other medicinal products for the treatments of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1 of the Invokana SmPC.

Click here for Invokana® (canagliflozin) United Kingdom Prescribing Information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone 0800 085 8678 or email: [email protected]

PP-IN-UK-3219 | October 2025

A. Menarini Farmaceutica Internazionale SRL have had no input into the contents of the footer and are not affiliated with the links. GPnotebook is responsible for the contents of the footer.

This site is intended for UK-registered healthcare professionals only
GPnotebook

To continue, please confirm that you are a UK-registered healthcare professional by clicking one of the buttons below

Yes, I am a UK-registered healthcare professional
No, I am not a UK-registered healthcare professional

You are leaving https://resources.gpnotebook.com

Text

Text

Close

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel